| |
|
Form Serial Number: |
DA20200604E00260
|
| 1.
Date of relevant event: |
28/05/2020
(dd/mm/yyyy)
|
| 2.
Date when director became aware of the relevant event/ interest in the shares (if later): |
(dd/mm/yyyy)
|
| 3.
Stock code: |
09939 |
| 4.
Name of listed corporation: |
Kintor Pharmaceutical Ltd. - B |
| 5.
Class of shares: |
Ordinary Shares |
| 6.
Number of issued shares in class: |
369,389,600 |
| 7.
Name of director (English) as printed on HKID Card/Passport: |
| (Surname) |
LU |
| (Other names) |
GANG |
|
|
|
| 10.
Name of director (Chinese): |
陆刚 |
| 11.
Chinese Character Code as printed on HKID Card: |
|
| |
| 24.
Details of relevant event: |
|
|
Brief description of relevant event
|
Capacity in which shares were/are held
|
Number of shares bought/sold or involved
|
Currency of transaction |
On Exchange
|
Off Exchange
|
|
Before relevant event
|
After relevant event
|
Highest price (per share)
|
Average price (per share)
|
Average consideration (per share)
|
Consideration code
|
| Long position |
| 1101 | The number of shares in which you are interested has increased because:
you purchased the shares |
|
|
|
10,000 |
HKD |
15.8800 |
15.8800 |
|
|
| Short position |
|
|
|
|
|
|
|
|
|
| |
|
| 25.
Total shares in listed corporation immediately before the relevant event: |
| | Total number of shares | Percentage figure (%) |
| Long position | 0 | 0.00 |
|
| |
| 26.
Total shares in listed corporation immediately after the relevant event: |
| | Total number of shares | Percentage figure (%) |
| Long position | 10,000 | 0.00 |
|
| |
| 27.
Capacity in which interests disclosed in Box 26 are held: |
| Code describing capacity | Number of shares |
| | |
|
| |
| 28.
Further information in derivative interests in listed corporation : |
| Derivatives code |
Exercise period (dd/mm/yyyy) |
Consideration - if derivatives granted by listed corporation |
Number of shares |
| | | Begins | Ends | Currency | Price for grant | Currency | Exercise price | Currency | Price on assignment | |
| | | | | | | | | | | |
|
| |
| 29.
Further information in relation to interests of children under 18 and/or spouse: |
| Child/Spouse | Name of child/spouse | Number of shares |
| | |
|
| |
| 30.
Further information in relation to interests of corporations controlled by Director: |
| Name of controlled corporation | Address and place of incorporation | Name of controlling person | % control | Direct interest (Y/N) | Number of shares |
| | | | | |
|
| |
| 31.
Further information in relation to interests held by Director jointly with another person: |
| Name of joint shareholder | Address | Number of shares |
| | |
|
| |
| 32.
Further information from a director who is a trustee, or beneficiary of a trust, or a person who has set up a Discretionary Trust: |
| Names of Trust | Address | Status code | Number of shares |
| | | |
|
| |
| 33.
Further information from a party to an agreement under Section 317 (Please see Notes for further information required): |
| Names of other parties | Address | Number of shares |
| | |
| Total number of shares in which a director is interested under sections 317 and 318 | |
|
| |
| 34.
Supplementary information: |
陆刚先生于2020年5月28日首次购入Kintor Pharmaceutical Limited（“上市公司”）10,000股相关股份（“有关事件”）,因陆刚先生身为上市公司的董事，须根据《证券及期货条例》（第571章）披露持有该上市公司的股份的权益。紧接在有关事件之后，陆刚先生持有上市公司股份总数的0.003%。
|
| 35.
Log/Serial Number of the previous form: |
|
| 36.
Number of concert party document(s) under section 317 attached/uploaded: |
|
|
Date of filing this Form 3A: |
04/06/2020
(dd/mm/yyyy)
|
| |